Tango Therapeutics (TNGX) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 225.3% versus a loss of 18.5%. Over five years, VKTX leads with a +374.4% price change compared with +69.7% for TNGX. Tango Therapeutics is the larger company by market cap ($4.01 billion vs $3.63 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNGX | VKTX |
|---|---|---|
| Share price | $23.81 | $28.51 |
| Market cap | $4.01B | $3.63B |
| 1-day change | +5.49% | +2.81% |
| YTD return | +168.74% | -18.96% |
| 1-year return | +225.27% | -18.50% |
| 5-year return | +69.71% | +374.38% |
| EPS (TTM) | $-0.85 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.38M | $0 |
| Revenue growth (YoY) | +48.29% | — |
| Net income (latest FY) | $-101.59M | $-359.64M |
| Operating margin | -178.39% | — |
| Net margin | -162.85% | — |
| 52-week high | $34.39 | $43.15 |
| 52-week low | $6.69 | $25.77 |
| Distance from 52-week high | -30.76% | -33.93% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +89.75% | +232.20% |
| Average volume | 2.65M | 4.16M |
| Shares outstanding | 168.61M | 127.17M |
| Employees | 137 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed VKTX by 243.8 percentage points over the past year.
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
TNGX vs VKTX FAQ
Which is bigger, Tango Therapeutics or Viking Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $4.01B compared with $3.63B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, TNGX or VKTX?
TNGX returned +225.27% over the past 12 months, compared with -18.50% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Tango Therapeutics and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.